Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial) - Yin, Jun; Lin, Siyun; Fang, Yong; Jiao, Heng; Chen, Zongwei; Tang, Han; Gu, Jianmin; Zhang, Shaoyuan; Sun, Linyi; Li, Yin; Han, Yongtao; Chen, Qixun; et al. (Journal of thoracic disease, 2023)
Keywords: Study Protocol; neoadjuvant; nivolumab; adjuvant; chemotherapy; Esophageal squamous cell carcinoma (ESCC)